Advisory Alpha LLC Has $436,000 Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Advisory Alpha LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.2% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,074 shares of the medical research company’s stock after selling 557 shares during the quarter. Advisory Alpha LLC’s holdings in Thermo Fisher Scientific were worth $436,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. Nuveen LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. EdgePoint Investment Group Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after acquiring an additional 329,974 shares in the last quarter. Auto Owners Insurance Co raised its holdings in shares of Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after buying an additional 283,810 shares in the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Thermo Fisher Scientific by 18.3% during the 1st quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock worth $878,795,000 after buying an additional 272,747 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. UBS Group boosted their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Barclays boosted their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. TD Cowen boosted their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO stock opened at $558.28 on Thursday. The firm has a market capitalization of $210.81 billion, a P/E ratio of 32.25, a P/E/G ratio of 3.26 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock’s fifty day simple moving average is $508.04 and its 200 day simple moving average is $456.10.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the company posted $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 54,420 shares of company stock worth $28,134,684. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.